Guylaine Haché represents pharmaceutical company clients primarily in biotechnology and pharmaceutical patent matters, with an emphasis on patent litigation, patent prosecution, and day-to-day patent counseling. She brings to her work a Ph.D. in molecular biology and years of experience in Abbreviated New Drug Application cases, representing clients in district courts across the country, including in Delaware and New Jersey. Guylaine also has more than five years of experience preparing and prosecuting patent applications for a variety of technologies in the United States and abroad.
Prior to law school, Guylaine was a technical advisor and then patent agent at an international law firm, where she prepared and prosecuted numerous patent applications, in the United States and abroad, for clients and inventors from large corporations, startup companies and universities. Her responsibilities covered a range of technologies, including modified proteins, fusion proteins, nucleic acid therapeutics, antibody development, methods of treatment, diagnostic methods, drug formulations, and dosage regimens.
Guylaine's doctoral dissertation related to understanding the molecular mechanism by which a human protein called APOBEC3G inhibits the replication of human immunodeficiency virus. Her doctoral work led to nine publications in peer-reviewed journals, including Current Biology, PLoS Pathogens and Journal of Virology.
Chicago-Kent College of Law, 2016, J.D.
University of Minnesota, 2009, Ph.D. , Molecular Biology
Bemidji State University, 2004, B.S., Biology & Chemistry
US Court of Appeals for the Federal Circuit
US District Court for the Northern District of Illinois